Akademisyen
ERHAN APTULLAHOĞLU
DOKTOR ÖĞRETİM ÜYESİ (Unvan:Doçent)
BİLECİK ŞEYH EDEBALİ ÜNİVERSİTESİ FEN FAKÜLTESİ MOLEKÜLER BİYOLOJİ VE GENETİK BÖLÜMÜ
- Ana Dal Fen Bilimleri ve Matematik Temel Alanı
- Yan Dal Moleküler Biyoloji ve Genetik
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 18
- Proje 0
- Kitap 0
- Bildiri 0
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
12
Q2
4
Q3
0
Q4
0
WoS (JCR)
Q1
10
Q2
3
Q3
3
Q4
0
TR Index
2
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
1
Ort. yüzdelik
65.0%
Üst %1 payı
0.0%
Üst %10 payı
6.2%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2025 Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 79.2%
- 2025 Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 79.2%
- 2025 Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia YÖKSİS SJR Q1 JCR Q2 OpenAlex 89.2%
- 2025 Brigimadlin (BI-907828) and napabucasin (BBI608) cooperatively trigger apoptosis in chronic lymphocytic leukemia cells by simultaneous inhibition of MDM2 and STAT3 YÖKSİS SJR Q2 JCR Q3 OpenAlex 64.5%
- 2025 Kanser Tedavisinde PI3K/AKT/mTOR Yolunun Hedeflenmesi: Yeni Nesil mTOR İnhibitörlerine Güncel Bir Değerlendirme YÖKSİS TR Index OpenAlex 13.8%
- 2025 Preclinical Evaluation of Brigimadlin (BI 907828) As a Novel MDM2 Inhibitor in Acute Lymphoblastic Leukemia YÖKSİS TR Index OpenAlex 27.7%
- 2024 Targeting MDM2-mediated suppression of p53 with idasanutlin: a promising therapeutic approach for acute lymphoblastic leukemia YÖKSİS SJR Q1 JCR Q2 OpenAlex 84.1%
- 2024 RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 80.5%
- 2023 SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 85.2%
- 2023 Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition YÖKSİS SJR Q1 JCR Q1 OpenAlex 85.6%
- 2022 p53 as a biomarker and potential target in gastrointestinal stromal tumors YÖKSİS SJR Q2 JCR Q2 OpenAlex 78.6%
- 2019 Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells YÖKSİS SJR Q1 JCR Q1 OpenAlex 81.5%
- 2019 In situ detection of JAK2V617F within viable hematopoietic cells using gold nanoparticle technology YÖKSİS SJR Q2 JCR Q3 OpenAlex 54.9%
- 2017 Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 92.8%
- 2017 Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous melanoma cells YÖKSİS SJR Q1 JCR Q1
- 2016 The p53-MDM2 Antagonist RG7388 Activates p53 and Induces a Predominantly Pro-Apoptotic Gene Expression Signature in Chronic Lymphocytic Leukemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 27.2%
- 2014 In-Cell Detection By Flow Cytometry of JAK2 V617F Mutation Using Gold Nanoflares YÖKSİS SJR Q1 JCR Q1 OpenAlex 15.6%
- 2020 The spliceosome inhibitor E7107 induces a dosedependent cytotoxicity in CLL cells and produces aberrantly spliced transcripts and protein products of p53 pathway genes YÖKSİS SJR Q2 JCR Q3